A new model takes oxidative stress to heart

October 02, 2018

Oxidative stress - the molecular wear and tear that reactive oxygen species can exert on molecules and cells - has been linked to a range of human diseases, including heart failure and Alzheimer's disease. But the results of many clinical trials that tested the effects of combatting oxidative stress with simple remedies - such as vitamin supplements or blueberries - have painted a more complicated picture. For many years, researchers have been trying to tease out the nuances of the connections between oxidative stress and disease. But the diseases associated with oxidative stress typically involve multiple pathways in the body, and it has been challenging to define the specific roles of oxidative stress in disease progression at a molecular level. Investigators from Brigham and Women's Hospital have developed a robust new method for examining oxidative stress in the hearts of rodents in vivo to better understand the development and treatment of heart failure. Results of their novel methodology, applying a cutting-edge approach known as "chemogenetics," are published this week in Nature Communications.

"This is a new heart failure model that allows us to specifically study a critical player in heart disease: oxidative stress. This is the first time that we've been able to prove definitively that oxidative stress is a cause of heart failure," said Thomas Michel, MD, PhD, senior physician in the Brigham and Women's Hospital (BWH) Division of Cardiovascular Medicine and professor of medicine at Harvard Medical School.

Chemogenetics is an approach that allows researchers to activate or inactivate a recombinant protein in cells or tissues simply by providing or withdrawing the specific molecules that bind to the protein. The BWH researchers developed an in vivo method using this approach that allowed them to generate and measure a reactive oxygen species - hydrogen peroxide - specifically in the heart, and then monitor the onset of cardiac dysfunction. Michel's team is using this approach to create a more tractable preclinical model of heart failure to help increase the speed and scope of drug development and testing.

"A lot of the models of heart failure that have been used for drug development have moved forward one animal at a time," said Michel. "But with chemogenetics, a path is opening up for high-throughput screening of new heart failure drugs."

To examine oxidative stress on the heart, the research team took advantage of a D-amino acid oxidase (DAAO) - an enzyme that was cloned from yeast. DAAO is known to generate hydrogen peroxide (H2O2) only in the presence of D-amino acids, leading to oxidative stress. But mammalian cells use L-amino acids, not D-amino acids: a subtle but important difference that allows the introduced yeast enzyme to remain quiescent until it's provided with its D-amino acid substrate. The team used a virus to deliver DAAO to the hearts of rats, and then the animals were provided with drinking water containing a D-amino acid in order to activate the DAAO. After 4-5 weeks, the team examined hearts using echocardiography to measure cardiac function and heart size. Additionally, the researchers measured markers of inflammatory and adaptive stress.

Compared to animals that received a control virus, the rats expressing DAAO showed signs of advanced heart failure, including increased heart size and decreased contractile function, which were specifically caused by oxidative stress in the heart.

"We anticipate that chemogenetic approaches will enable future studies not only in the heart, but also in the many other organ systems where the relationship between redox events and disease remains unclear," said co-lead author Ben Steinhorn, a Harvard MD-PhD student who pursued his PhD in Michel's lab.

"Heart failure can now be examined in a rapid, reliable, and reversible manner," said co-lead author Andrea Sorrentino, a BWH postdoctoral research fellow. "Instead of doing surgery one animal at a time, we can deliver the virus to many animals at once, and then activate the DAAO enzyme just by providing its substrate in their drinking water to trigger specifically oxidative stress in the heart."

With funding from the Brigham and Women's Hospital Health and Technology Innovation Award, Michel's lab is also developing a transgenic mouse - an animal model whose genome has been altered to encode DAAO, allowing researchers to skip the viral vector and more easily study oxidative stress.
Funding for this work was supported by NIH grants PO1-HL48743 and RO1-HL46457 (to TM); T32-GM007753 (to BS); American Diabetes Association grant 9-17-CMF-012 (to AS) NIH T32-HL007604 (to SB); Brigham and Women's Hospital Health and Technology Innovation Award (to TM); and Russian Science Foundation grant 17-14-01086 and DFG IRTG 1816 (to VB).

Paper cited: Steinhorn, Benjamin et al., Chemogenetic generation of hydrogen peroxide (H2O2) in the heart induces severe cardiac dysfunction. Nature Communications. DOI: 10.1038/s41467-018-06533-2

Brigham and Women's Hospital

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.